Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R. Clamp, Jonathan A. Ledermann, James D. Brenton et al.|The Lancet Oncology|2022Cited by 45
Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statementSarah P. Blagden, A. Yiangou, Lucinda Billingham et al.|British Journal of Cancer|2020Cited by 44
#159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysisAndrew R. Clamp, Jonathan A. Ledermann, Iain A. McNeish et al.|International Journal of Gynecological Cancer|2023Cited by 4
ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysisA. Clamp, Jonathan A. Ledermann, Domenico Radice et al.|International Journal of Gynecological Cancer|2026Cited by 1